首页> 外文期刊>Allergy, Asthma & Immunology Research >Efficacy, Safety, and Immunomodulatory Effect of the Intramuscular Administration of Autologous Total Immunoglobulin G for Atopic Dermatitis: A Randomized Clinical Trial
【24h】

Efficacy, Safety, and Immunomodulatory Effect of the Intramuscular Administration of Autologous Total Immunoglobulin G for Atopic Dermatitis: A Randomized Clinical Trial

机译:肌肉内诊断肌肉内诊断的疗效,安全性和免疫调节效应,用于特应性皮炎的肌内免疫球蛋白G:随机临床试验

获取原文
获取外文期刊封面目录资料

摘要

PURPOSE:The management of patients with atopic dermatitis (AD) is often difficult. We hypothesized that repeated intramuscular administration of autologous total immunoglobulin G (IgG) could induce clinical improvement in patients with AD through immune modulation. This clinical trial was conducted to evaluate the efficacy, safety, and immunomodulatory effect of the intramuscular administration of autologous total IgG in patients with AD.METHODS:In this randomized, double-blind, placebo-controlled trial, 51 adolescent and adult patients with moderate-to-severe AD were randomized to receive 8 weekly intramuscular administrations of autologous total IgG 50 mg (n = 26) or saline (n = 25) over a 7-week period and were followed up to week 16. Changes in the clinical severity score (Eczema Area and Severity Index), affected body surface area, patient-reported Dermatology Life Quality Index (DLQI) score, laboratory biomarkers, and incidence of adverse events from baseline to week 16 were assessed.RESULTS:The intramuscular administration of autologous total IgG, compared with saline, decreased the clinical severity score (-64.8% vs. -20.3%, P 0.001), reduced the affected body surface area (-53.9% vs. -19.1%, P 0.001), improved the DLQI score (-35.4% vs. -14.4%, P = 0.015), increased serum interleukin-10 and interferon-γ levels (P = 0.011 and P = 0.003, respectively), and reduced the incidence of AD exacerbation (11.5% vs. 48.0%, P = 0.004) from baseline to week 16. No serious adverse events were observed.CONCLUSIONS:The intramuscular administration of autologous total IgG provided clinical improvements and a systemic immunomodulatory effect in adolescent and adult patients with moderate-to-severe AD without significant side effects.TRIAL REGISTRATION:Clinical Research Information Service Identifier: KCT0001597.Copyright ? 2020 The Korean Academy of Asthma, Allergy and Clinical Immunology · The Korean Academy of Pediatric Allergy and Respiratory Disease.
机译:目的:患有特应性皮炎(广告)的患者的管理往往是困难的。我们假设重复的自体免疫球蛋白G(IgG)的重复肌肉内施用可以通过免疫调节诱导AD患者的临床改善。进行了该临床试验以评估Ad.Methods患者肌内IgG肌内IgG的肌肉内施用的疗效,安全性和免疫调节作用:在该随机,双盲,安慰剂对照试验中,51例青少年和成年患者中度 - 在7周的时间内随机AD被随机预期接受8每周一次每周80mg(n = 26)或盐水(n = 25)的盐水(n = 25),并进行最多为第16周。临床严重程度的变化评估分数(湿疹地区和严重程度指数),受影响的体表面积,患者报告的皮肤科生活质量指数(DLQI)得分,实验室生物标志物和来自基线的不良事件的发生率为16周。结果:自体总量的肌肉内给药与盐水相比,IgG减少了临床严重程度(-64.8%vs. -20.3%,p <0.001),减少了受影响的体表面积(-53.9%vs. -19.1%,p <0.001),改善了DLQI得分(-35.4% vs. -14.4%,p = 0.015),增加血清白细胞介素-10和干扰素-γ水平(P = 0.011和p = 0.003),降低了广告加剧的发生率(11.5%与48.0%,P =从基线到第16周。没有观察到严重的不良事件。结论:自体的肌肉内施用总IgG为青少年和成年患者的临床改善和全身免疫调节作用提供了中度至严重的广告,没有显着副作用.Trial注册:临床研究信息服务标识符:KCT0001597.COPYRIGHT? 2020韩国哮喘学院,过敏和临床免疫学·韩国儿科过敏和呼吸系统院。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号